Arthritis, Cardiovascular Diseases, Chronic Pain, Diabetes Mellitus, Type 2, Mental Disorders, Pain
Conditions
Keywords
Genetic Variation, Genetic Polymorphism, Polymorphism, Single Nucleotide, Genetic Association Studies, Healthcare Utilization
Brief summary
The purpose of this study is to evaluate the impact of genetic testing on healthcare decisions and patient outcomes for patients suffering from pain, cardiovascular problems, Arthritis, Type II Diabetes, and/or Mental Health disorders. Results of genetic testing will also be compared with the clinical outcome measures collected to discover novel genetic factors that may influence patient care.
Detailed description
The molecular basis of many pharmacogenetic polymorphisms has now been elucidated, with genetic variations resulting in alteration of expression or function of receptors, enzymes, and transporters relevant to the safety and efficacy of a medical treatment. Genetics has been shown to be a significant factor in the variability of responses of medication choices and doses. With the rapid development of cost-effective high throughput molecular genotyping methods, pharmacogenetics has become increasingly important because of its potential to identify patients with increased risk of adverse drug reactions or decreased likelihood of response at standard dosage of drug. By identifying the genetic risks and the most effective therapy for an individual patient, clinicians may improve the efficacy of treatment and decrease the risk of adverse drug events. The addition of pharmacogenetic testing to routine clinical practice may also be extremely helpful because of the cost reduction associated with the identification of patients that will not respond to expensive drugs or with the identification of patients likely to suffer from severe adverse events. There are also tremendous efforts in the pharmaceutical industry to lower the cost for drug development; pharmacogenetics may fulfill the need to provide the right drug to the right patient and to increase the likelihood of success of large phase II and phase III clinical trials. The purpose of this study is to evaluate how currently available genetic tests are being implemented in various clinics around the United States, and whether this information results in benefits to patient care. Patients presenting to clinics with pain, cardiovascular conditions, Arthritis, Type II Diabetes, and/or Mental Health disorders that are receiving Proove Bioscience's genetic testing will complete validated questionnaires to measure specific outcomes related to their treatment at each clinical visit, including medication efficacy, reduction in adverse drug events, and healthcare utilization. Physicians will document any changes made to treatment regimens, including adjustments to medications or non-pharmacological treatments, and any improvements in the outcome measures. Statistical analysis will be performed to calculate relationships between genotypic and phenotypic data points collected in this study. The results of this study will provide a measurable understanding of the medical and economic value of implementing genetic testing into clinical care. Furthermore, data points collected will be used to examine novel correlations and associations between single nucleotide polymorphisms and longitudinal clinical outcome measures.
Interventions
OTHERUnblinded to Genetic Testing Results
The physicians of this group of patients will be unblinded to the results of the genetic testing.
OTHERBlinded to Genetic Testing Results
The physicians of this group of patients will be blinded to the results of the genetic testing. They will be un-blinded to the results of each patient once that patient has completed the study.
Sponsors
Proove Bioscience, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Provide signed and dated informed consent form * Willing to comply with all study procedures and be available for the duration of the study * Male or Female, at least 18 years of age * Currently taking or a candidate for medication * Documented or recent complaint within 90 days with initial date of onset
Exclusion criteria
* Severe hepatic or renal disease (where current pharmaceutical dosing is affected and/or requires adjustment of standard dosing prior to PGx testing) * Significant diminished mental capacity that is unable to understand the protocol, surveys and questionnaires; unable to read/write English or Spanish. * Recent febrile illness that precludes or delays participation by more than 1 month * Pregnancy or lactation * Participation in a clinical study that may interfere with participation in this study * Anything that would place the individual at increased risk or preclude the individual's full compliance with or completion of the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Glucose levels for patients being treated for T2DM | 60 days | — |
| Frequency of participant urine drug screens | Up to 2 years | — |
| Risk of stroke using the CHA2DS2-VASc Score | 60 days | — |
| Severity of Rheumatoid Arthritis using the Routine Assessment of Patient Index Data (RAPID-3) score | 60 days | — |
| BMI for patients being treated for T2DM | 60 days | — |
| Self-rated response levels to prescribed medications | 60 days | Subjects are ask to rate the ability of their medication, on a scale of 0 to 5, to treat their condition and/or relieve their symptoms. |
| Presence and Severity of Generalized Anxiety Disorder on the GAD-2 | 60 days | — |
| Presence and Severity of Depression on the PHQ-2 | 60 days | — |
| Presence of atrial fibrillation symptoms and their impact on quality of life using the Severity of Atrial Fibrillation (SAF) scale | 60 days | — |
| Pain Scores on the Pain Numeric Rating Scale (NRS) | 60 days | — |
| Function/Disability assessment on the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) | 60 days | — |
| Number of Participants that Experience of Adverse Events | Up to 2 years | — |
| Type of Adverse Events Experienced by Participants | Up to 2 years | — |
| Severity of Adverse Events Experienced by Participants | Up to 2 years | — |
| Type of medication or alternative therapy prescribed for participants, as listed on the Medication Efficacy Differentiation (MED) Scale or on the investigator's evaluation form | Up to 2 years | — |
| Medication dosage prescribed to the participants | Up to 2 years | — |
| Risk of cardiovascular incidents using the AHA Heart Disease Risk Assessment | 60 days | — |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Co-occurring disorders collected by ICD-9/10 codes | 60 days | — |
| Assessment of previous treatments | 60 days | Participants are asked to rate the benefit of previous treatments on a scale of 0 to 5. |
| Urine drug screen results | 60 days | — |
Countries
United States
Outcome results
None listed